
A new version of Novo Nordisk's once-weekly diabetes drug Ozempic looks to be on the road to European patients, the pharmaceutical company reports in a press release.
Novo Nordisk thus announces on Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has suggested that Ozempic be approved in a new dose of its active ingredient of 2.0 mg. Ozempic, which is a GLP-1 analog, is used in the treatment of diabetes patients with type 2 diabetes, which is already approved in the doses of 0.5 mg and 1.0 mg.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app